ISRCTN75843298已完成未知
orth Thames CA125 study in advanced ovarian cancer: a randomised controlled trial
K Co-ordinating Committee for Cancer Research (UKCCCR)0 个研究点目标入组 237 人开始时间: 2001年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 237
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Histologically confirmed diagnosis of invasive epithelial ovarian carcinoma
- •2. International Federation of Gynaecology and Obstetrics (FIGO) stage Ic, II, III or IV
- •3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
- •4. Aged 18 - 75 years
- •5. Adequate renal, hepatic and bone marrow function
- •6. Life expectancy of at least 3 months
- •7. No history of previous malignancy, except basal cell carcinoma of the skin or in situ carcinoma of the cervix
- •8. No medical contra-indications to protocol treatments
排除标准
- •Does not comply with above inclusion criteria.
研究者
相似试验
已完成
3 期
Phase III Randomized Trial of Maintenance Pegylated Liposomal Doxorubicin (PLD)/ Carboplatin versus without in Patients with Advanced Ovarian CancerAdvanced ovarian cancerCancer - Ovarian and primary peritonealACTRN12607000329460Chang Gung Memorial Hospital122
已完成
不适用
Sentinel node in ovarian cancermalignancy of the ovary10038594ovarian cancerNL-OMON37538Medisch Universitair Ziekenhuis Maastricht28
已完成
不适用
European Randomised Trial of Ovarian Cancer Screening IICancerISRCTN79217590Cancer Research UK (CRUK) (UK)
进行中（未招募）
不适用
Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyPlatinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or treatment free interval < 6 months after stop of platinum based chemotherapy)EUCTR2007-003089-16-DEAGO Research GmbH72
终止
不适用
Improving communication about treatment options for asymptomatic ovarian cancer patients with rising cancer antigen 125 (CA-125): A randomised controlled trial of a Decision AidCommunication about treatment options and decision making for women with asymptomatic ovarian cancer and rising CA-125 levels.Cancer - Ovarian and primary peritonealACTRN12609001035213Centre for Medical Psychology and Evidence-based Decision-making178